| Autor: |
Brett Gm, Hughes, Elizabeth, Ahern, Margot, Lehman, Gary, Pratt, Margaret, Dauth, Wendy, Pritchard, Leesa, Wockner, Keith, Horwood |
| Rok vydání: |
2016 |
| Předmět: |
|
| Zdroj: |
Asia-Pacific journal of clinical oncology. 13(3) |
| ISSN: |
1743-7563 |
| Popis: |
Despite recent advances, outcomes for patients with stage III non-small cell lung cancer (NSCLC) with concurrent chemoradiotherapy (CRT) remain poor. We evaluated the combination of ciplatin/vinorelbine and concurrent thoracic radiotherapy followed by consolidation oral vinorelbine in this phase II study.Eligible patients with unresectable stage III NSCLC received cisplatin intravenous (IV) 40 mg/mTwenty-seven eligible patients were enrolled from December 2007 to June 2010 before the trial was prematurely closed due to toxicity concerns. The median age was 63 years (range, 42-71), 56% were male, 52% ECOG 0 and 52% stage IIIa. The ORR was 81% (including 37% complete response rate) and disease control rate of 93%. The median PFS was 11 months and median OS was 26 months. Consolidation vinorelbine was associated with significant grade 3/4 toxicity (68%) including grade 3-5 febrile neutropenia (27%) and respiratory infections (36%) including two deaths in the consolidation phase (9%).Consolidation oral vinorelbine after CRT was associated with significant toxicity. Overall, this regimen achieved a high ORR and survival results comparable to other CRT protocols but the significant toxicity precludes further evaluation of this approach. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Plný text